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Objective: To determine if a human bladder cancer-specific peptide named PLZ4 can target canine bladder cancer
cells.
Experimental Design: The binding of PLZ4 to five established canine invasive transitional cell carcinoma (TCC) cell
lines and to normal canine bladder urothelial cells was determined using the whole cell binding assay and an
affinitofluorescence assay. The WST-8 assay was performed to determine whether PLZ4 affected cell viability. In vivo
tumor-specific homing/targeting property and biodistribution of PLZ4 was performed in a mouse xenograft model
via tail vein injection and was confirmed with ex vivo imaging.
Results: PLZ4 exhibited high affinity and specific dose-dependent binding to canine bladder TCC cell lines, but not
to normal canine urothelial cells. No significant changes in cell viability or proliferation were observed upon
incubation with PLZ4. The in vivo and ex vivo optical imaging study showed that, when linked with the near-
infrared fluorescent dye Cy5.5, PLZ4 substantially accumulated at the canine bladder cancer foci in the mouse
xenograft model as compared to the control.
Conclusions and Clinical Relevance: PLZ4 can specifically bind to canine bladder cancer cells. This suggests that
the preclinical studies of PLZ4 as a potential diagnostic and therapeutic agent can be performed in dogs with
naturally occurring bladder cancer, and that PLZ4 can possibly be developed in the management of canine
bladder cancer.
Background
Recently, we have developed a bladder cancer-specific
peptide named PLZ4 (the amino acid sequence:
cQDGRMGFc) that specifically binds to human bladder
transitional cell carcinoma (TCC) cell lines and to can-
cer cells obtained from five different clinical patient spe-
cimens in vitro and in vivo [1]. Currently, we are
conducting the preclinical studies to determine the diag-
nostic and targeted therapeutic potential of PLZ4. One
major problem we have encountered is that the mouse
models commonly used for preclinical studies are
neither physiologically nor physically applicable to
human bladder cancer. In contrast, dogs with naturally
occurring bladder TCC can serve as a spontaneous,
outbred, immune-competent, large animal model for
TCC in the human [2,3]. Bladder tumors in dogs possess
similar histopathological appearance, molecular features,
biological behavior, and response to chemotherapy as do
bladder TCC in humans [4,5]. Therefore, we determined
whether PLZ4 could bind to canine bladder cancer. If so,
this peptide can potentially be developed for the diagnos-
tic and therapeutic purposes in the management of
canine bladder cancer, since bladder TCC is the most
common urinary cancer in dogs (87% of all cases) [6].
Findings
To determine the binding of PLZ4 to canine invasive
TCC cell lines, a whole cell binding assay was performed
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any medium, provided the original work is properly cited.(Additional File 1). We first synthesized PLZ4 on
TentaGel S NH2 resin beads (Rapp Polymere Gmbh,
Germany) [1,7], and incubated the PLZ4-coated beads
with 10
6 cells/ml single-cell suspensions of five differ-
ent canine invasive TCC cell lines including K9TCC-
PU, K9TCC-PU-AxA, K9TCC-PU-In, K9TCC-PU-AxC,
and K9TCC-PU-Nk (kindly provided by Deborah
Knapp at Purdue University, West Lafayette, IN, USA)
[3]. Human bladder cancer cell line 5637 cells served
as the positive control. Over 95% of the bead surface
was covered with 5637 and K9TCC cells (Figure 1A: a
and 1A: b, respectively). In contrast, there was no cell
binding and a smooth bead surface was observed when
the beads were incubated with the normal canine blad-
der urothelial cells (Figure 1A: c), or bladder cells from
a dog with chronic cystitis (Figure 1A: d).
To further evaluate the binding of PLZ4 to canine TCC
cell lines, we conducted an affinitofluorescence assay.
PLZ4 was synthesized and covalently conjugated to
biotin. Canine TCC cell lines were cultured on chamber
slides. Normal urothelial cells from dogs euthanized for
non-bladder diseases were isolated and then made into
a single-cell suspension before cytospin slide prepara-
tions were performed. Slides were fixed with acetone for
2 min before blocking. Cells were incubated with 1 μM
of PLZ4-biotin for 1 hour at 4°C, then with SA-Alexa
Flour
® 488 conjugate (Invitrogen, Carlsbad, CA, USA)
at 1:1000 dilution per manufacturer’sp r o t o c o l .A f t e r
washing, the slides were mounted with DAPI-containing
medium for nuclear staining (blue), and observed under
inverted fluorescence microscope (200 X). All five
canine TCC cell lines showed diffuse cell membrane
staining (Figure 1 B: c. fluorescence staining of K9TCC-
PU), while no significant staining was observed with
normal canine urothelial cells (Figure 1B: a).
To further quantify the binding affinity, K9TCC-PU
and K9TCC-PU-In cells were seeded in 96-well plates,
fixed with acetone, and incubated with increasing
ab d c ab d
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Figure 1 PLZ4 binds to Canine TCC cells. A. whole cell binding assay to determine cell binding specificity of PLZ4. Cells were resuspended at
10
6 cells/ml and incubated with beads coated with PLZ4. If PLZ4 binds to cells in solution, bead surface would be covered with cells and
exhibit a rosette pattern under the microscopy examination. This experiment was repeated 3 times for cell lines. The cell binding assay of
normal canine bladder urothelial cells was repeated on 3 different dogs. a. 5637 human bladder cancer cell line; b. K9TCC-PU cell line; c. normal
canine urothelial cells; d. urothelial cells from a bladder with chronic cystitis. The average diameter of the beads is 90 μm. B. Affinitofluorescence
of PLZ4 peptide toward Canine TCC cell lines. Affinitofluorescence staining was performed with all five canine TCC cell lines and normal canine
bladder urothelial cells of dogs euthanized for non-bladder diseases. Only fluorescence staining to normal urothelial cells (a) and K9TCC-PU cells
(c) was shown. b and d showed the corresponding DAPI nuclear staining of a and c, respectively.
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shown in Figure 2A, PLZ4 exhibited a dose-dependent
binding against canine TCC cell lines. The Kd50 values
of PLZ4 for K9TCC-PU and K9TCC-PU-In (the concen-
tration of PLZ4 to saturate 50% of cell surface receptor)
were 21.3 and 10.3 μM, respectively, while the Kd50
value for human 5637 cells was 6.67 μM.
Ligand binding to cell surface molecules may initiate cell
signaling and exert biological effects on cells. Here, we
determined the effect of PLZ4 on cell viability and prolif-
eration, as these PLZ4-mediated effects may have potential
clinical applications. K9TCC, K9TCC-PU-In and K9TCC-
PU-Nk cells were seeded in 96-well plates and incubated
without or with various concentrations of PLZ4 for 48
hours. The WST-8 cell proliferation assay was performed
per manufacturer’s protocol (Cayman Chemical, Ann
Arbor, MI, USA). There were no significant changes in
cell proliferation/viability in these three cell lines cultured
with different concentrations of PLZ4 when compared to
the control cells treated with PBS (Figure 2B).
Next, we determined the tumor-specific homing/
targeting property and in vivo biodistribution/binding
specificity of PLZ4 in a mouse model with canine TCC
xenografts. The near-infrared fluorescent dye Cy5.5 was
used for in vivo and ex vivo imaging. PLZ4-biotin-SA-
Cy5.5 (PLZ4-Cy5.5) complex or SA-Cy5.5 dye (control),
100 μl (6 nmol) for each mouse, was injected via tail
vein into mice carrying TCC-PU-In xenografts at 0.5-0.8
cm in diameter. Substantial accumulation of signals was
observed at the tumor site in the mice injected with
PLZ4-Cy5.5 complex in a time-dependent manner with
a maximum signal observed at 12 hours (Figure 3A). In
contrast, negligible fluorescence uptake of Cy5.5 dye by
tumors was detected in the control mice receiving
SA-Cy5.5. To determine if there was any non-specific
uptake of the dye by other vital organs, mice were
euthanized at 12 hours after injection, vital organs and
cancer xenografts were removed for ex vivo imaging
(Figure 3B). Both liver and kidney demonstrated consid-
erable signals even in the control mice that received SA-
Cy5.5, suggesting the non-specific uptake. Compared
with the tumor xenografts from the control mice treated
with SA-Cy5.5, xenografts from the mice that received
PLZ4-Cy5.5 accumulated significantly higher fluores-
cence signals after normalization with the fluorescence
signal in liver (3.2 times, p = 0.003) and kidney (3.8
times, p < 0.001) (Figure 3C). No significant fluores-
cence uptake was observed in other organs including
bladder. Collectively, these data demonstrated that PLZ4
exhibited excellent homing property toward TCC xeno-
grafts in vivo.
Discussion
This is the first study showing that a human bladder can-
cer-specific peptide can also target canine bladder TCC
cells. During drug development, immunocompromised
mice with tumor xenografts are most often used for precli-
nical studies. Physiologically, mouse xenograft models are
radically different from naturally occurring cancer in
human patients. The most commonly used xenograft




























Figure 2 Binding Affinity and biological effects of PLZ4 against
canine TCC cell lines. A. Binding affinity of PLZ4 against K9TCC-PU
and K9TCC-PU-In. Twenty thousands cells of K9TCC-PU and K9TCC-
PU-In were seeded in 96 well plates. After culture for 24 hours, cells
were fixed and incubated with different concentrations of PLZ4-
biotin for 1.5 hours followed by SA-HRP for another 1 hour. Cells
treated with SA-HRP alone served as background control. The color
was developed using TMB substrate and read by ELISA readers.
Three independent experiments conducted in triplicate were
performed. The mean values of the 3 experiments are shown.
B. Biological effects of PLZ4 on canine TCC cell lines. Ten thousand
cells of K9TCC-PU-In or K9TCC-PU were seeded in the 96-well plates
and treated with increasing concentrations of PLZ4 or PBS for
2 days. The cell proliferation assay was assessed by the WST-8 assay
per manufacturer’s protocol. Cells treated with PBS were used as
100% control. Each experiment was performed three times in
triplicate. Mean values at each concentration are presented.
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Page 3 of 6Figure 3 Homing of PLZ4 to mouse xenograft of canine bladder cancers. Nude mice with the xenografts from TCC-PU-In at 0.5-0.8 cm in
diameter were randomly selected to be injected with 100 μl (6 nmol) of pre-incubated PLZ4-biotin-SA-Cy5.5 complex or SA-Cy5.5 dye as the
control. Total body imaging was performed at 0, 1, 3, 6, and 12 hours after injection. All experiments were conducted in compliance with
institutional guidelines and according to the protocol (No. 12988) approved by the Institutional Animal Care and Use Committee of the
University of California at Davis. A. In vivo imaging of canine K9TCC-PU-In xenografts with PLZ4. In vivo near-infrared fluorescence images were
taken at different time points after injection. C: the control mouse that received SA-Cy5.5. PLZ4: the mouse that received PLZ4-Cy5.5. Red arrows
point to tumor xenografts. B. Ex vivo imaging of organs and tumor xenografts for fluorescence intensity. A color bar with the fluorescence
intensity in arbitrary units is shown at the bottom. C. Ex vivo quantitative analysis of fluorescence uptake in tumor xenografts. The fluorescence
intensity of tumor xenografts was normalized to that of the liver and kidney of the same mouse (the normalized value of liver and kidney is
defined as 1.0).
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the subcutaneous space. Furthermore, because of the rapid
tumor formation (weeks) in xenograft models, the local
vasculature formation and permeability can be dramati-
cally different from that of naturally occurring cancer that
usually take months to years to develop. Here we showed
that PLZ4 can bind to canine bladder cancer cells both in
vitro and in vivo (Figures 1 and 3). Consistent with our
previous finding that PLZ4 could bind to primary bladder
cancer cells from five different human patients but not to
urine cells collected from four cancer-free patients actively
receiving Bacillus Calmette-Guérin treatment [1], PLZ4
could bind to cancer cells from one canine bladder TCC
clinical specimen, but not to a bladder lymphoid hyperpla-
sia specimen from another dog patient (data not shown),
or a bladder with chronic cystitis (Figure 1d). Our findings
suggest that most of the preclinical studies of PLZ4 can be
performed and validated in dogs with naturally occurring
bladder cancer. Furthermore, the US Food and Drug
Administration requires that the pharmacology and toxi-
cology studies in two species of mammalian animals
(usually in rats and dogs) be performed before the first-in-
human study can be conducted.
One major application of PLZ4 is local visualization of
bladder cancer during transurethral resection of bladder
cancer (TURBT). It is clinically relevant since incom-
plete resection is seen in up to one third of cases after
TURBT that contributes to the high recurrence of blad-
der cancer after therapy [8]. Fluorescence cystoscopy
with 5-Aminolevulinic acid (ALA) has been used for
this purpose [9]. But nonspecific uptake of ALA by non-
cancer urothelial cells, especially in inflamed bladder,
precludes its wide clinical application. PLZ4 binds to
canine bladder cancer cells, but not to normal urothelial
cells or cells from a bladder with chronic cystitis (Figure 1).
This suggests that fluorescence cystoscopy with PLZ4 con-
jugated to a fluorescent dye can be an excellent candidate
for this application, and that dogs with naturally occurring
bladder cancer can be an outstanding model. The Kd50 of
PLZ4 at 10.29 and 21.31 μM can be easily achievable with
l o c a li n t r a v e s i c a li n s t i l l a t i o n .
Our in vivo targeting and biodistribution study
showed that PLZ4 specifically concentrated at the tumor
sites, but not to other sites including bladder (Figure 3).
Therefore, PLZ4 has the potential to be developed for
imaging detection of bladder cancer by conjugated to
imaging agents, such as iron oxide for MRI (magnetic
resonance imaging) and radioisotope for PET/SPECT
(positron emission tomography/single photon emission
computed tomography). Both MRI and PET scans have
been used for the diagnosis of canine malignancies.
Another potential application is targeted therapy by
conjugating PLZ4 to toxin or chemotherapeutic drugs.
In our in vivo studies (Figure 3), only 6 nmol (equivalent
to 17 mg of PLZ4 in a 75-Kg patient) of PLZ4-Cy5.5
was used, and little non-specific uptake was observed. This
is consistent with our previous findings that PLZ4 did not
bind to any of the confounding cells that possibly exist
inside the bladder such as normal urothelial cells, whole
blood, peripheral blood mononuclear cells, fibroblasts, and
vascular endothelial cells. This specific binding is critical
for in vivo targeting with PLZ4 conjugates.
In summary, the human bladder cancer-specific pep-
tide PLZ4 can bind to canine bladder cancer cells, sug-
gesting that the preclinical studies of PLZ4 can be
performed in dogs with naturally occurring bladder TCC.
Additional material
Additional file 1: Materials and Methods. A detail description of the
materials and methods for this publication.
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